A1480LS
A1480LS is a peripherally restricted, orally active covalent and irreversible inhibitor of DAGLα and DAGLβ, with IC50 values of 6 nM and 4 nM against human targets, respectively, and IC50 values ≤15 nM across mouse, rat, dog, monkey and human systems. A1480LS reduces the levels of 2-arachidonoylglycerol, arachidonic acid, and cyclooxygenase- and lipoxygenase-derived eicosanoids. A1480LS inhibits injury-induced production of 2-arachidonoylglycerol and arachidonic acid in the peripheral sciatic nerve, and suppresses the responses of high-threshold and wide-dynamic-range-like dorsal horn neurons to mechanical stimulation. A1480LS alleviates pain behaviors in rat models of inflammatory pain, neuropathic pain and chemotherapy-induced peripheral neuropathy.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 分子式: C30H25F3N6O
- 分子量:542.55
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
|
DAGLα |
DAGLβ |
A1480LS (15, 20 mg/kg; p.o.) rapidly alleviates and continuously inhibits paclitaxel-induced mechanical hyperalgesia in rats during 5 consecutive days of administration. It also reverses and maintains CCI-induced mechanical allodynia in rats to the sham operation level, while restoring the injury-induced elevated levels of 2-AG and AA in the sciatic nerve to normal, without affecting the levels of these lipids in the brain[1].
A1480LS (1 mg/kg; i.v.) selectively inhibits the activity of HT and WDR-like dorsal horn neurons in anesthetized CCI rats without altering the activity of LTMRs, indicating that it suppresses spinal nociceptive sensory input[1].
A1480LS (8-30 mg/kg; p.o.) does not modulate PTZ-induced seizure susceptibility or brain 2-AG levels in rats, is well tolerated in rats, with only mild, transient reduction in abdominal muscle tone observed in some animals; these findings indicate that it poses no central nervous system epileptogenic risk[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague Dawley (male, 176-206 g, intraplantar CFA injection)[1]
-
Dosage:1 mg/kg; 2.5 mg/kg; 5 mg/kg; 10 mg/kg; 20 mg/kg
-
Administration:p.o.; 2 doses (2 h before CFA, 24 h after CFA)
-
Result:Increased mechanical withdrawal thresholds dose-dependently 4 h after the second dose, with an ED50 of 7.7 mg/kg.
Achieved average blood concentrations of 1.1 μM (free plasma concentrations=1.5 nM) at 20 mg/kg, with an EC50 of 0.22 μM to suppress allodynia.
Inhibited kidney DAGLβ activity and reduced kidney 2-AG concentrations dose-dependently.
Caused partial brain DAGLα/β inhibition at 10 and 20 mg/kg without brain 2-AG depletion.
-
Animal Model:Sprague Dawley (male, intraperitoneal paclitaxel injection 1 mg/kg daily for 5 consecutive days)[1]
-
Dosage:15 mg/kg (single dose; established allodynia); 15 mg/kg (repeated dosing; maintained anti-allodynic effects)
-
Administration:p.o.; single dose on day 7; once daily for 5 days (days 15-18)
-
Result:Attenuated established mechanical allodynia 4 h post-dose on day 7 with a single 15 mg/kg oral dose.
Maintained significant anti-allodynic effects over 5 days with repeated once-daily dosing of 15 mg/kg from days 15-18, comparable to duloxetine.
-
Animal Model:Sprague Dawley (male, 200-220 g at surgery; 233-289 g at dosing, chronic constriction injury of left common sciatic nerve)[1]
-
Dosage:20 mg/kg (repeated dosing; allodynia reversal); 20 mg/kg (single dose; lipid analysis)
-
Administration:p.o.; once daily for 5 days (days 14-18); single dose 14 days post-CCI
-
Result:Reversed allodynia and restored von Frey thresholds to sham levels with repeated 20 mg/kg dosing, with efficacy comparable to naproxen and pregabalin.
Reduced 2-AG and normalized AA concentrations in injured sciatic nerves with a single 20 mg/kg dose, after CCI caused a 7-fold increase in 2-AG and 2-fold increase in AA.
-
Animal Model:Sprague Dawley (male, 250-315 g, chronic constriction injury of left sciatic nerve, right jugular vein catheter implantation)[1]
-
Dosage:0.1 mg/kg; 0.3 mg/kg; 1 mg/kg
-
Administration:i.v.; single bolus after baseline vehicle recording
-
Result:Produced dose-dependent modulation of high-threshold (HT) and wide dynamic range-like (WDR-like) single-unit responses, with robust suppression at 1 mg/kg.
Did not modulate low-threshold mechanoreceptor (LTMR) single-unit activity at 1 mg/kg.
-
Animal Model:Sprague Dawley (male, 208-263 g, subcutaneous pentylenetetrazole injection 80 mg/kg)[1]
-
Dosage:8 mg/kg; 16 mg/kg; 30 mg/kg
-
Administration:p.o.; single dose 4 h pre-PTZ
-
Result:Did not alter convulsion latency or occurrence at any tested dose.
Did not change brain 2-AG levels following administration.
化学情報
-
分子量 542.55
-
分子式 C30H25F3N6O
-
SMILES
O=C(N1CCN(C[C@@H]1CC2=CC=CC=C2)C3=NC(C(F)(F)F)=CN=C3)N4C=C5C=C(C=CC5=N4)C6=CC=CC=C6
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
A1480LS 関連分類
HY-181482 関連分類
Powered by Bioz